Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has entered into a partnership with US-based Neomorph to discover, develop, and commercialize molecular glue degraders targeting specific indications in cardiometabolic and rare diseases. Neomorph will be responsible for the discovery and pre-clinical development of the candidates, for which it will receive up to USD 1.46 billion in upfront payments, milestone payments, funding, and sales royalties on successful molecules. Novo Nordisk will have the option to take over clinical trials and commercialization efforts.
Founded in 2020, Neomorph specializes in protein degradation and the development of molecular glues against ‘undruggable’ targets. The company’s pipeline is focused on oncology, marking this partnership as an expansion into the cardiometabolic and rare disease sector.- Flcube.com
